^
    13d
    Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> May 2027
    Trial completion date
    |
    Lynparza (olaparib) • Recentin (cediranib)
    16d
    CLIP2 is a potential biomarker for platinum resistance and prognosis in ovarian cancer: a bioinformatics analysis. (PubMed, Transl Cancer Res)
    Drug sensitivity analysis revealed that high CLIP2 expression conferred resistance to platinum-based agents, topotecan, and gemcitabine, but heightened sensitivity to olaparib, cediranib, and pictilisib. Through bioinformatic analysis, this study proposes CLIP2 as a potential biomarker associated with platinum resistance and immune microenvironment patterns in ovarian cancer. These preliminary findings provide a basis for subsequent mechanistic studies and larger validation cohorts to confirm its clinical relevance in guiding immunotherapy and targeted treatment approaches.
    Journal • PARP Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • ADORA2A (Adenosine A2a Receptor) • CD48 (CD48 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    Lynparza (olaparib) • gemcitabine • pictilisib (GDC-0941) • topotecan • Recentin (cediranib)
    22d
    Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysis. (PubMed, BMC Cancer)
    Bevacizumab was associated with improved PFS, but not OS compared to standard therapy and other targeted therapies in newly diagnosed GBM patients. Exploratory subgroup findings suggested that nivolumab may be associated with less favorable OS and PFS estimates in MGMT-unmethylated patients. SUCRA rankings should be interpreted as exploratory because most interventions were supported by limited trial evidence. However, certain targeted drugs exhibit inadequate safety profiles, and careful risk-benefit assessment is required. Future research should further explore safer and more effective multi-targeted combination strategies to overcome GBM's survival bottleneck.
    Retrospective data • Journal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • temozolomide • Recentin (cediranib) • TheraCIM (nimotuzumab) • depatuxizumab mafodotin (ABT-414) • marizomib (NPI-0052)
    1m
    Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling. (PubMed, NPJ Precis Oncol)
    In this study, we evaluated a novel liquid biopsy platform based on circulating cell-free DNA active chromatin (cfDNAac) profiling to identify baseline biomarkers associated with clinical benefit rate (CBR) in 30 LMS patients treated with durvalumab plus olaparib or cediranib. In this analysis, cfDNAac profiling represents a promising non-invasive strategy to predict clinical benefit from CPI-based therapy in LMS. Prospective validation in independent cohorts is warranted to clarify its clinical utility.
    Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    1m
    A tumor microenvironment-focused signature based on m6A and lactylation modification predicts prognosis and immunotherapy response in hepatocellular carcinoma. (PubMed, Discov Oncol)
    Specifically, the high-risk group exhibited increased immune cell infiltration, lower IC50 values for several drugs including 5-fluorouracil, afatinib, crizotinib, cediranib, taselisib, and staurosporine; Whereas the low-risk group displayed reduced stromal component proportions and better responses to entinostat, irinotecan, KRAS inhibitors, cisplatin, axitinib, and topotecan. The lactylation-m6A related prognostic model exhibited robust predictive efficiency in HCC. TCOF1 and HDAC1 may be promising tumor biomarkers for HCC and more researches are needed to validate these results.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • HDAC1 (Histone Deacetylase 1)
    |
    cisplatin • Xalkori (crizotinib) • Gilotrif (afatinib) • 5-fluorouracil • irinotecan • axitinib • taselisib (GDC-0032) • topotecan • Jingzhuda (entinostat) • Recentin (cediranib)
    1m
    NCI-2015-01097: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=122, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 expression • ALK mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    1m
    Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027
    Trial completion date
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    1m
    Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    1m
    SWOG S0905: Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P1/2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    cisplatin • pemetrexed • Recentin (cediranib)
    1m
    NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P3, N=579, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027
    Trial completion date • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    1m
    Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... (clinicaltrials.gov)
    P1/2, N=268, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Apr 2026 --> Oct 2027 | Trial completion date: Jul 2026 --> Oct 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    2ms
    NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027
    Trial completion date • Platinum resistant
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)